¡Ú»À²½¥¹¥È¥ì¥¹¡¦±ê¾É¤ÈÀº¿À¼À´µ¡Û
Åý¹ç¼ºÄ´¾É¤ÎÉÂÂ֤ˤϰäÅÁŪÍ×°ø¤ä´Ä¶ÅªÍ×°ø¤¬¿¼¤¯Íí¤ß¹ç¤Ã¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤Æ¤ª¤ê¡¤¿ô¿¤¯¤ÎÉÂÂÖ²¾À⤬Ä󾧤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¶áǯ¡¤»À²½Åª¥¹¥È¥ì¥¹¤ä±ê¾É¤¬¡¤Åý¹ç¼ºÄ´¾É¤ÎÉÂÂ֤˿¼¤¯¤«¤«¤ï¤Ã¤Æ¤¤¤ë¤³¤È¤¬È½¤Ã¤Æ¤¤Þ¤·¤¿¡£
Do KQ, Conus P and Cuenod M¡Ê2010¡ËRedox dysregulation and oxidative stress in schizophrenia¡§ nutrigenetics as a challenge in psychiatric disease prevention. J Nutrigenet Nutrigenomic, 3¡Ê4¨¡6¡Ë¡§ 267¨¡289
Î㤨¤Ð¡¤À¸ÂÎÆâ¤Î»À²½Åª¥¹¥È¥ì¥¹¤Ë¤«¤«¤ï¤ë¹³»À²½Êª¼Á¥°¥ë¥¿¥Á¥ª¥ó¤¬¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎǾÀÔ¿ñ±ÕÃæ¤ÇͰդ˸º¾¯¤·¤Æ¤¤¤ë¤³¤È¡¤¤Þ¤¿¥×¥í¥È¥óMRS¤òÍѤ¤¤¿¸¦µæ¤«¤é¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎÁ°Æ¬Èé¼Á¤Ë¤ª¤±¤ë¥°¥ë¥¿¥Á¥ª¥óÇ»ÅÙ¤¬Í°Õ¤ËÄã²¼¤·¤Æ¤¤¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¤Þ¤·¤¿¡£
Do KQ, Trabesinger AH, Kirsten¨¡Kruger M, et al ¡Ê2000¡ËSchizophrenia¡§glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci, 12¡Ê10¡Ë¡§ 3721¨¡3728.
É®¼Ô¤é¤Ï¡¤Ç¾Æ⥰¥ë¥¿¥Á¥ª¥óÇ»Å٤ȱ¢À¾É¾õ¤Î½Å¾ÉÅ٤δ֤ËÉé¤ÎÁê´Ø´Ø·¸¤¬¤¢¤ë¤³¤È¤òÊó¹ð¤·¤Þ¤·¤¿¡£
Potvin S, Stip E, Sepehry AA, et al¡Ê2008¡Ë Inflammatory cytokine alterations in schizophrenia¡§ a systematic quantitative review. Biol Psychiatry, 63 ¡Ê8¡Ë¡§ 801¨¡808.
¤Þ¤¿¡¤¥°¥ë¥¿¥Á¥ª¥ó¤ÎÁ°¶îÂΤǤ¢¤ëN¨¡acetyl cysteine¡ÊNAC¡Ë¤ÎÅý¹ç¼ºÄ´¾É´µ¼Ô¤Î±¢À¾É¾õ¤Ë¤ª¤±¤ë¼£ÎŸú²Ì¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
Berk M, Copolov D, Dean O, et al¡Ê2008¡ËN¨¡acetyl cysteine as a glutathione precursor for schizophrenia ¨¡a double¨¡blind, randomized placebo¨¡controlled trial. Biol Psychiatry, 64¡Ê5¡Ë¡§ 361¨¡368.
¤µ¤é¤Ë¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤Î·ì±ÕÃæ¤Î±ê¾ÉÀ¥µ¥¤¥È¥«¥¤¥óÇ»ÅÙ¤¬¡¤·ò¾ï¼Ô¤ÈÈæ³Ó¤·¤ÆͰդ˹⤤¤³¤È¤¬¡¤¥á¥¿²òÀϤ«¤é¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
Potvin S, Stip E, Sepehry AA, et al¡Ê2008¡Ë Inflammatory cytokine alterations in schizophrenia¡§ a systematic quantitative review. Biol Psychiatry, 63 ¡Ê8¡Ë¡§ 801¨¡808.
¤Þ¤¿¡¤¡Î11C¡ÏPK111195¡ÊËö¾¿À¥Ù¥ó¥¾¥¸¥¢¥¼¥Ô¥ó¼õÍÆÂÎÙɹ³Ìô¡Ë¤òÍѤ¤¤¿PET¡Êpositron emission tomography¡Ë¸¦µæ¤«¤é¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎǾ¤Ç¤Ï¡¤¥ß¥¯¥í¥°¥ê¥¢¤Î³èÀ²½¤¬µ¯¤¤Æ¤¤¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
Hashimoto K¡Ê2008¡ËMicroglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry, 32¡Ê7¡Ë¡§ 1758¨¡1759.
¢¨¥ß¥¯¥í¥°¥ê¥¢¡§Ç¾¤äÀÔ¿ñ¤Ë¸ºß¤¹¤ëÌȱֺÙ˦¤Ç¡¢Ãæ¿õ¿À·Ð·Ï¤ò¹½À®¤¹¤ëºÙ˦¤ÎÌ󣵡Á£²£°¡ó¤òÀê¤á¤ë¡£Àµ¾ï¾õÂ֤ǤϺÙŤ¤Æ͵¯¤òÆ°¤«¤·¤Ê¤¬¤é¼þ°Ï¤Î´Ä¶¤ò´Æ»ë¤·¤Æ¤¤¤ë¡£¤·¤«¤·¡¢¿À·ÐºÙ˦¤Î¾ã³²¤Ê¤É¤Ë¤è¤ê¡¢²áÅ٤˳èÀ²½¤¹¤ë¤È¡¢±ê¾ÉÀʪ¼Á¡Ê±ê¾ÉÀ¥µ¥¤¥È¥«¥¤¥ó¤Ê¤É¡Ë¤ò»ºÀ¸¤·¡¢¿À·ÐºÙ˦¤Îµ¡Ç½°Û¾ï¤Ê¤É¤ò°ú¤µ¯¤³¤¹¤³¤È¤¬ÃΤé¤ì¤Æ¤¤¤ë¡£
ºÇ¶á¡¤»×½Õ´ü¤Ë¤ª¤±¤ëNAC¤ÎÅêÍ¿¤¬¡¤¿·À¸»ù¤Î³¤ÇÏÇ˲õ¥â¥Ç¥ë¤ÎÀ®½Ï´ü¤Ë¤ª¤±¤ëÀº¿ÀɤÎȯ¾É¤òͽËɤǤ¤ë¤³¤È¤ò¼¨¤¹ÏÀʸ¤¬È¯É½¤µ¤ì¤Þ¤·¤¿¡£
Cabungcal JH, Counotte DS, Lewis EM, et al¡Ê2014¡Ë Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron, 83¡Ê5¡Ë¡§ 1073¨¡1084.
¤³¤Î¤è¤¦¤Ë¡¤Á°Î×¾²»î¸³¥â¥Ç¥ë¤Ë¤ª¤¤¤Æ¡¤¹³»À²½Êª¼ÁNAC¤Ï¡¤Åý¹ç¼ºÄ´¾É¤Ê¤É¤ÎÀº¿À¼À´µ¤Îȯ¾É¤òͽËɤǤ¤ë²ÄǽÀ¤¬¤¢¤ê¤Þ¤¹¡£
¥Ï¥¤¥ê¥¹¥¯»ù¤òÍѤ¤¤¿¸¦µæ¤«¤é¡¤Åý¹ç¼ºÄ´¾É¤Ê¤É¤ÎÀº¿Àɤ˰ܹԤ¹¤ë³ä¹ç¤Ï¡¤Ìó30¡óÄøÅ٤Ǥ¢¤ë¤³¤È¤«¤é¡¤Àº¿ÀɤÎͽËɤȤ¤¤¦´ÑÅÀ¤«¤é¤¹¤ë¤È¡¤°ÂÁ´¤Ê²½¹çʪ¤¬Ë¾¤Þ¤ì¤Þ¤¹¡£
Î㤨¤Ð¡¤Àĵû¤Ë´Þ¤Þ¤ì¤ëω3 »éËûÀ¤Ï¡¤¥Ï¥¤¥ê¥¹¥¯»ù¤ÎÀº¿ÀɤؤΰܹԤòÍ°Õ¤ËÄã²¼¤µ¤»¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¡¤ÃíÌܤµ¤ì¤Þ¤·¤¿¡£
Amminger GP, Schäfer MR, Papageorgiou K, et al ¡Ê2010¡ËLong¨¡chain omega¨¡3 fatty acids for indicated prevention of psychotic disorders¡§a randomized, placebo¨¡controlled trial. Arch Gen Psychiatry, 67¡Ê2¡Ë¡§ 146¨¡154.
¤³¤Î¤è¤¦¤Ë¡¤¿©»ö¤È¤·¤ÆÀݼè²Äǽ¤Ê²½¹çʪ¤Ë¤è¤ê¡¤Àº¿À¼À´µ¤ÎͽËɤ¬²Äǽ¤Ç¤¢¤ì¤Ð¡¤Àº¿À¼À´µ¤ÎͽËɤȤ¤¤¦´ÑÅÀ¤«¤é¤¹¤ë¤È¡¤Èó¾ï¤Ë½ÅÍפǤ¹¡£
ºÇ¶á¡¤É®¼Ô¤é¤ÏÅý¹ç¼ºÄ´¾É´µ¼Ô¤òÂоݤȤ·¤¿¥ª¡¼¥×¥ó¸¦µæ¤Ç¡¤sulforaphane´ÞͤΥ֥í¥Ã¥³¥ê¡¼Ãê½Ðʪ¤¬¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎǧÃε¡Ç½¾ã³²¤ò²þÁ±¤¹¤ë¤³¤È¤ò¸«½Ð¤·¤Þ¤·¤¿¡£
Shiina A, Kanahara N, Sasaki T, et al¡Ê2015¡ËAn open study of sulforaphane¨¡rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci, In press.
¤µ¤é¤Ë¡¤2014 ǯ10 ·î¤ËÊƹñ¤ÎHarvardÂç³Ø¤ÈJohns HopkinsÂç³Ø¤Î¸¦µæ¼Ô¤¬¡¤¼«Êľɥ¹¥Ú¥¯¥È¥é¥à¾ã³²¤òÂоݤȤ·¤¿¥×¥é¥»¥ÜÂоȻ¤Çsulforaphane´ÞͤΥ֥í¥Ã¥³¥ê¡¼Ãê½Ðʪ¤¬Í°Õ¤Ë¼«Êľɾɾõ¤ò²þÁ±¤¹¤ë¤³¤È¤òÊó¹ð¤·¤Þ¤·¤¿¡£
Singh K, Connors SL, Macklin EA, et al¡Ê2014¡Ë Sulforaphane treatment of autism spectrum disorder ¡ÊASD¡Ë. Proc Natl Acad Sci USA, 111¡Ê43¡Ë¡§ 15550- 15555.
Japanese Journal of Biological Psychiatry Vol.26, No.1, 2015